Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020264156 - ASYMMETRIC DIMETHYLARGININE (ADMA) AS A MARKER FOR VASCULAR PATHOLOGIES

Publication Number WO/2020/264156
Publication Date 30.12.2020
International Application No. PCT/US2020/039613
International Filing Date 25.06.2020
IPC
G01N 33/68 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
A61P 25/28 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
CPC
A61P 25/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
G01N 2800/2814
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
28Neurological disorders
2814Dementia; Cognitive disorders
G01N 2800/2821
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
28Neurological disorders
2814Dementia; Cognitive disorders
2821Alzheimer
G01N 2800/32
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
32Cardiovascular disorders
G01N 2800/52
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
52Predicting or monitoring the response to treatment; Prognosis
G01N 33/6812
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
6803General methods of protein analysis not limited to specific proteins or families of proteins
6806Determination of free amino acids
6812Assays for specific amino acids
Applicants
  • MUSC FOUNDATION FOR RESEARCH DEVELOPMENT [US]/[US]
  • THE U.S. GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS [US]/[US]
Inventors
  • SINGH, Inderjit
  • SINGH, Avtar, K.
Agents
  • BYRD, Marshall, P.
Priority Data
62/866,13625.06.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ASYMMETRIC DIMETHYLARGININE (ADMA) AS A MARKER FOR VASCULAR PATHOLOGIES
(FR) DIMÉTHYLARGININE ASYMÉTRIQUE (ADMA) EN TANT QUE MARQUEUR DE PATHOLOGIES VASCULAIRES
Abstract
(EN)
The present disclosure provides methods for the detection of levels of ADMA to determine the risk of a vascular or neurological pathology.
(FR)
La présente invention concerne des méthodes qui permettent de détecter des niveaux d'ADMA pour déterminer le risque d'une pathologie vasculaire ou neurologique.
Latest bibliographic data on file with the International Bureau